Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Mizuho Maintains Neutral on Neoleukin Therapeutics, Lowers Price Target to $1.5

Author: Benzinga Newsdesk | May 09, 2023 10:04am
Mizuho analyst Mara Goldstein maintains Neoleukin Therapeutics (NASDAQ:NLTX) with a Neutral and lowers the price target from $2 to $1.5.

Posted In: NLTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist